CXBS (Corix Bioscience) ROCE %: -17.55% (As of Sep. 2017)


What is Corix Bioscience ROCE %?

Corix Bioscience CXBS -99.00% ROCE % is -17.55% as of Sep. 2017.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Corix Bioscience's annualized ROCE % for the quarter that ended in Sep. 2017 was -17.55%.

Corix Bioscience  (OTCPK:CXBS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Corix Bioscience ROCE % Related Terms

Corix Bioscience ROCE % Historical Data

* Premium members only.

The historical data trend for Corix Bioscience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience ROCE % Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
ROCE %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -37.86

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.27 -114.40 -2.43 -62.91 -17.55

Corix Bioscience ROCE % Calculation

Corix Bioscience's annualized ROCE % for the fiscal year that ended in Dec. 2016 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2016 )  (A: Jan. 2015 )(A: Dec. 2016 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2016 )  (A: Jan. 2015 )(A: Dec. 2016 )
=-4.045/( ( (0 - 0) + (11.37 - 0.687) )/ 1 )
=-4.045/( (0+10.683)/ 1 )
=-4.045/10.683
=-37.86 %

Corix Bioscience's ROCE % of for the quarter that ended in Sep. 2017 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2017 )  (Q: Jun. 2017 )(Q: Sep. 2017 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2017 )  (Q: Jun. 2017 )(Q: Sep. 2017 )
=-1.124/( ( (10.457 - 1.205) + (4.344 - 0.786) )/ 2 )
=-1.124/( ( 9.252 + 3.558 )/ 2 )
=-1.124/6.405
=-17.55 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2017) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -17.55% mean?
Corix Bioscience (CXBS) has a ROCE % of -17.55% as of Sep. 2017.
Is Corix Bioscience's ROCE % too high?
Corix Bioscience's current ROCE % is -17.55%.
How does Corix Bioscience's ROCE % compare to BKIT and YBAO?
Corix Bioscience's ROCE % of -17.55% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corix Bioscience's current ROCE % is -17.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corix Bioscience stock overvalued right now?
Corix Bioscience (CXBS) has a current ROCE % of -17.55%. The current ROCE % is -17.55%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Corix Bioscience (CXBS), the current ROCE % is -17.55% as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corix Bioscience Business Description

Address 18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.